In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he
An NHS England technology funding enterprise, the Small Business Research Initiative (SBRI) Healthcare, secured over £30 million in savings for its parent organisation and reached over mill
The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic drugs, which are considered to be “equally effective alternatives
Vertex remains at loggerheads with NHS England over funding for Orkambi, but said it would consider the body’s most recent offer of a £500 million, five-year funding deal.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.